Research

In recent years, ASO (antisense oligonucleotide) therapies have been transforming the landscape of rare genetic diseases. Several treatments have been approved and dozens more are in development. Although we don't yet know whether thisapproach will be applicable to the LMBRD2 gene, it's important to understand these advances and their implications.